Danaher announces 9.9 billion dollar Masimo acquisition. The diagnostics company expects the deal to deliver 0.15 to 0.20 dollars per share accretion in year one, scaling to 0.70 dollars by year five through identified synergies. The transaction would reduce the EBITDA multiple to 15x. However, concerns linger regarding Danaher's recent track record of value creation and premium acquisition pricing. The company's leverage has risen to approximately 3.2x, raising questions about financial flexibility. While Danaher maintains a strong long-term acquisition history, recent performance metrics and elevated valuation multiples suggest caution is warranted for investors evaluating this strategic move.
Post from MarketNews_en
Log in to interact with content.